Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1999 1
2001 1
2012 2
2013 3
2014 4
2016 1
2017 1
2020 1
2021 2
2023 1
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

14 results

Results by year

Filters applied: . Clear all
Page 1
Targeted Investigational Oncology Agents in the NCI-60: A Phenotypic Systems-based Resource.
Morris J, Kunkel MW, White SL, Wishka DG, Lopez OD, Bowles L, Sellers Brady P, Ramsey P, Grams J, Rohrer T, Martin K, Dexheimer TS, Coussens NP, Evans D, Risbood P, Sonkin D, Williams JD, Polley EC, Collins JM, Doroshow JH, Teicher BA. Morris J, et al. Among authors: lopez od. Mol Cancer Ther. 2023 Nov 1;22(11):1270-1279. doi: 10.1158/1535-7163.MCT-23-0267. Mol Cancer Ther. 2023. PMID: 37550087 Free PMC article.
F-aza-T-dCyd (NSC801845), a Novel Cytidine Analog, in Comparative Cell Culture and Xenograft Studies with the Clinical Candidates T-dCyd, F-T-dCyd, and Aza-T-dCyd.
Morris J, Wishka DG, Lopez OD, Rudchenko V, Huang G, Hoffman SN, Borgel S, Georgius K, Carter J, Stotler H, Kunkel MW, Collins JM, Hollingshead MG, Teicher BA. Morris J, et al. Among authors: lopez od. Mol Cancer Ther. 2021 Apr;20(4):625-631. doi: 10.1158/1535-7163.MCT-20-0738. Mol Cancer Ther. 2021. PMID: 33811149 Free PMC article.
The development of β-selective glycosylation reactions with benzyl substituted 2-deoxy-1,4-dithio-D-erythro-pentofuranosides: enabling practical multi-gram syntheses of 4'-Thio-2'-deoxycytidine (T-dCyd) and 5-aza-4'-thio-2'-deoxycytidine (aza-T-dCyd) to support clinical development.
Wishka DG, Lopez OD, Rudchenko VF, Huang G, Bahde R, Kumar V, Denysenko SM, Zhang L, Zhang M, Teicher BA, Morris J. Wishka DG, et al. Among authors: lopez od. Nucleosides Nucleotides Nucleic Acids. 2021;40(1):68-95. doi: 10.1080/15257770.2020.1832694. Epub 2020 Oct 16. Nucleosides Nucleotides Nucleic Acids. 2021. PMID: 33063584
Hepatitis C virus NS5A replication complex inhibitors: the discovery of daclatasvir.
Belema M, Nguyen VN, Bachand C, Deon DH, Goodrich JT, James CA, Lavoie R, Lopez OD, Martel A, Romine JL, Ruediger EH, Snyder LB, St Laurent DR, Yang F, Zhu J, Wong HS, Langley DR, Adams SP, Cantor GH, Chimalakonda A, Fura A, Johnson BM, Knipe JO, Parker DD, Santone KS, Fridell RA, Lemm JA, O'Boyle DR 2nd, Colonno RJ, Gao M, Meanwell NA, Hamann LG. Belema M, et al. Among authors: lopez od. J Med Chem. 2014 Mar 13;57(5):2013-32. doi: 10.1021/jm401836p. Epub 2014 Feb 12. J Med Chem. 2014. PMID: 24521299
Development of the Large-Scale Synthesis of Tetrahydropyran Glycine, a Precursor to the HCV NS5A Inhibitor BMS-986097.
Mathur A, Wang B, Smith D, Li J, Pawluczyk J, Sun JH, Wong MK, Krishnananthan S, Wu DR, Sun D, Li P, Yip S, Chen BC, Baran PS, Chen Q, Lopez OD, Yong Z, Bender JA, Nguyen VN, Romine JL, Laurent DRS, Wang G, Kadow JF, Meanwell NA, Belema M, Zhao R. Mathur A, et al. Among authors: lopez od. J Org Chem. 2017 Oct 6;82(19):10376-10387. doi: 10.1021/acs.joc.7b01852. Epub 2017 Sep 14. J Org Chem. 2017. PMID: 28877441
Biotransformation of Daclatasvir In Vitro and in Nonclinical Species: Formation of the Main Metabolite by Pyrrolidine δ-Oxidation and Rearrangement.
Li W, Zhao W, Liu X, Huang X, Lopez OD, Leet JE, Fancher RM, Nguyen V, Goodrich J, Easter J, Hong Y, Caceres-Cortes J, Chang SY, Ma L, Belema M, Hamann LG, Gao M, Zhu M, Shu YZ, Humphreys WG, Johnson BM. Li W, et al. Among authors: lopez od. Drug Metab Dispos. 2016 Jun;44(6):809-20. doi: 10.1124/dmd.115.068866. Epub 2016 Mar 30. Drug Metab Dispos. 2016. PMID: 27029743
HCV NS5A replication complex inhibitors. Part 4. Optimization for genotype 1a replicon inhibitory activity.
St Laurent DR, Serrano-Wu MH, Belema M, Ding M, Fang H, Gao M, Goodrich JT, Krause RG, Lemm JA, Liu M, Lopez OD, Nguyen VN, Nower PT, O'Boyle DR 2nd, Pearce BC, Romine JL, Valera L, Sun JH, Wang YK, Yang F, Yang X, Meanwell NA, Snyder LB. St Laurent DR, et al. Among authors: lopez od. J Med Chem. 2014 Mar 13;57(5):1976-94. doi: 10.1021/jm301796k. Epub 2013 Apr 10. J Med Chem. 2014. PMID: 23573957
HCV NS5A replication complex inhibitors. Part 5: discovery of potent and pan-genotypic glycinamide cap derivatives.
Belema M, Nguyen VN, St Laurent DR, Lopez OD, Qiu Y, Good AC, Nower PT, Valera L, O'Boyle DR 2nd, Sun JH, Liu M, Fridell RA, Lemm JA, Gao M, Knipe JO, Meanwell NA, Snyder LB. Belema M, et al. Among authors: lopez od. Bioorg Med Chem Lett. 2013 Aug 1;23(15):4428-35. doi: 10.1016/j.bmcl.2013.05.040. Epub 2013 May 23. Bioorg Med Chem Lett. 2013. PMID: 23803586
14 results